Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Image Credit: US Food and Drug Administration

On January 13, 2026, AliveCor announced that the US Food and Drug Administration (FDA) has cleared the next generation of KAI 12L, the AI powering the Kardia 12L Electrocardiogram (ECG) System, for five additional cardiac determinations.

Kardia 12L is the world’s first AI-powered handheld 12-lead ECG system – this clearance brings the device’s total number of cleared determinations up to 39. These new determinations include 3 

 – short PR interval, atrial bigeminy, and ventricular bigeminy – and 2 axis-related morphology determinations – Left Axis Deviation (LAD) and Right Axis Deviation (RAD).

“We are continuously expanding the diagnostic capabilities of our AI, and this latest clearance puts even more power into the hands of clinicians, delivering a high-fidelity 12-lead ECG, whose portable form can be deployed in any location, even in the most restricted or unconventional care settings,” Priya Abani, chief executive officer of AliveCor, said in a statement. “This milestone further solidifies AliveCor’s leadership in AI-powered cardiology as we continue to disrupt traditional care pathways and drive greater efficiency for healthcare providers.”

The device itself is battery-operated and weighs 0.3 pounds, making it substantially smaller and more portable than standard 12-lead ECG machines. It is also significantly less invasive by virtue of not requiring patients to fully disrobe before a reading.

Kardia 12L was first launched in June 2024, after which point it saw substantial growth in the US and expansion into India, Australia, and New Zealand. Additionally, according to AliveCor’s press release, the system has identified >4000 instances of myocardial infarction and ischemia. Recent research from August of 2025 reinforced the device’s efficacy, during which time patients visiting the electrophysiology clinic at Northwestern Memorial Hospital were given a Kardia 12L ECG rather than a standard 12-lead ECG.

During this trial, a total of 50 patients were administered a Kardia 12L ECG, with a primary indication for electrophysiology clinic appointments being for evaluation of atrial fibrillation or atrial flutter (74%) or premature ventricular contractions (6%). The most common recorded rhythms on the Kardia 12L ECG were normal sinus rhythm (60%), atrial and/or ventricular paced (20%), atrial fibrillation (10%), and sinus rhythm with premature ventricular contractions (10%).

Investigators saw that average time of Kardia 12L ECG acquisition was substantially shorter than that of a standard 12L ECG (Kardia 12L: 7.1 [6.2-8.3] minutes; standard 12L: 10 [8.7-12] minutes; 

 <.001) A total of 5 patients initially had a Kardia 12L ECG and necessitated an additional standard 12L ECG – reasons for this acquisition included poor signal quality (n = 2) and inability to definitively measure the QT interval due to printer settings (n = 3).

The investigators ultimately concluded that Kardia 12L offers a substantial time advantage over traditional 12L ECGs, without sacrificing diagnostic reliability. A low necessity for follow-up dedicated 12L ECGs further supports its role in the clinical setting.

AliveCor, Inc. AliveCor Announces FDA Clearance of New Cardiac Determinations for Kardia 12L ECG System, Bringing Total to 39. 

. January 13, 2026. Accessed January 13, 2026. 

https://www.globenewswire.com/news-release/2026/01/13/3217859/0/en/AliveCor-Announces-FDA-Clearance-of-New-Cardiac-Determinations-for-Kardia-12L-ECG-System-Bringing-Total-to-39.html

Gaddam M, Peigh G, Banani S, Passman RS. Efficiency of an artificial intelligence-aided portable 12-lead Electrocardiogram Acquisition System. Heart Rhythm O2. 2025;6(8):1232-1233. 

Articles

AliveCor's Kardia 12L, an AI-powered handheld 12-lead ECG system, has received FDA clearance for five additional cardiac determinations, increasing its total to 39. The device, launched in 2024, is portable, battery-operated, and less invasive than standard ECG machines. It has demonstrated efficacy in identifying myocardial infarction and ischemia, with recent research showing a significant reduction in acquisition time compared to traditional ECGs. The Kardia 12L's portability and efficiency make it a valuable tool in diverse clinical settings, enhancing diagnostic capabilities without compromising reliability.

The KAI 12L program is now cleared to determine short PR interval, atrial bigeminy, ventricular bigeminy, left axis deviation, and right axis deviation.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

FDA News

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Arrhythmia

FDA Clears AI Program Powering Kardia 12L Electrogram for 5 New Cardiac Determinations

Samar Hafida, MD | Image Credit: Twitter/X

On January 13, 2026, the Obesity Association, a division of the American Diabetes Association, published the next section in the 

Standards of Care in Overweight and Obesity

, titled “Pharmacologic Treatment of Obesity in Adults,” in the inaugural edition of 

Diabetes, Obesity, and Cardiometabolic CARE

The 23-page document spotlights pharmacotherapy’s role in reducing weight and improving weight maintenance compared to placebo, citing several clinical trials to support the drugs’ efficacy compared to placebo. However, the authors also stress the value of patient-centered shared decision-making in prescribing medication, encouraging a focus on each patient’s individual needs.

“The establishment of the Obesity Association, and now its associated journal, marks a significant advancement toward a future where the management of cardiometabolic diseases is unified, proactive, and grounded in a thorough understanding of their biological origins,” Samar Hafida, MD, vice president of the Obesity Association, said in a statement. “Through the 

, we continue to build the body of trusted, evidence-based guidelines in 

The guidelines suggest that a reduction in baseline body weight of ≥5% for adults treated with obesity medications shows significant health benefits and improvements in cardiometabolic risk factors. For patients with obesity-related diseases and complications, however, the authors encourage a reduction of ≥10% in baseline body weight, while a 10-15% reduction resulted in improvements in glycemia, blood pressure, and lipids compared to a 5-10% loss. Additionally, the guidelines highlight emerging data that suggest that ≥15% weight reduction may be required in some cases.

The document goes on to highlight commonly weight-promoting medications for conditions such as 

, providing alternative treatment suggestions to avoid excess weight gain. For example, the authors suggest replacing hypertension medications such as alpha blockers, metoprolol, propranolol, and atenolol with ACE inhibitors, ARBs, carvedilol, thiazides, and nebivolol.

Additionally, the guidelines emphasize the value of intensive behavioral therapy or structured lifestyle programs, as combining lifestyle changes with medication results in consistently greater weight reduction and health benefits. Nutritional counseling is also listed as a crucial factor in obesity management, particularly for patients on obesity medications. This is due in large part to the appetite-suppressing mechanics central to many treatment options, which may leave patients susceptible to inadequate nutrition through diminished hunger and its effects.

The authors also state that individuals with limited or partial responses to a given medication may be able to combine this medication with another, so that health care providers can target different pathways of weight regulation. Low-dose combination therapy has shown comparatively greater weight reduction than high-dose monotherapy in several randomized control trials.

Notably, the guidelines also spotlight obesity management during pregnancy, specifying that all approved obesity medications are currently contraindicated in patients who are pregnant or are actively trying to conceive. Some medications have been associated with fetal harm, such as topiramate, which is associated with major congential malformations. To this end, the guidelines suggest that patients considering pregnancy stop obesity medication ≥2 months prior to a planned pregnancy, accompanied by intensification of lifestyle behavioral therapy to accommodate.

Ultimately, these recommendations align with the Obesity Association’s broader work, which aims to change the conversation on obesity care and recognize obesity as the complex disease it is.

“The ADA’s Obesity Association encourages health care professionals to adopt and implement the present recommendations on obesity medications as part of a comprehensive obesity treatment plan for adults,” the ADA Professional Practice Committee for Obesity wrote. “Evidence supports the use of obesity medications in combination with lifestyle interventions to achieve long-term health and weight reduction goals.”

American Diabetes Association. The Obesity Association Publishes New Standards of Care Section on Obesity Medications. 

https://www.prnewswire.com/news-releases/the-obesity-association-publishes-new-standards-of-care-section-on-obesity-medications-302659817.html

American Diabetes Association Professional Practice Committee for Obesity*; Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. 

The Obesity Association, part of the American Diabetes Association, has released new guidelines on pharmacologic treatment for obesity, emphasizing the importance of patient-centered decision-making. The guidelines highlight the efficacy of obesity medications in achieving significant weight loss and improving cardiometabolic risk factors. They also recommend alternative medications to avoid weight gain and stress the importance of combining pharmacotherapy with lifestyle interventions. Special considerations are given for obesity management during pregnancy, advising against the use of obesity medications. The guidelines aim to enhance comprehensive obesity care.

These recommendations simultaneously emphasize the efficacy of weight loss drugs and encourage incorporating lifestyle therapy on top of medication.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

ADA’s Obesity Association Releases Guidelines for Use of Obesity Medications

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

 undergoing maintenance dialysis may reverse the survival advantage observed in the “obesity paradox” among patients with chronic disease, according to new research.

The findings highlight increased mortality, adverse clinical outcomes, longer hospital length of stay, and higher costs among patients with malnourished obesity compared with non-malnourished patients within this study population.

“Our findings show that obesity is significantly associated with lower in-hospital mortality among ESKD patients without malnutrition,” wrote study investigator Charat Thongprayoon, MD, an associate professor of medicine at Mayo Clinic, and colleagues. “However, when malnutrition coexists, this survival advantage is reversed, underscoring the importance of detecting malnutrition in obese ESKD patients.”

Globally, approximately 2.5 million individuals with ESKD are at increased risk of hospitalization and mortality, with nutritional imbalance considered one of the most critical risk factors for disease complications. Conversely, hospitalization for any illness among patients with ESKD increases susceptibility to malnutrition. Although malnutrition is commonly associated with undernutrition, the World Health Organization has noted malnutrition also occurs in overweight and obese individuals.

The “obesity paradox” in chronic disease, including ESKD, describes improved survival outcomes among patients with a body mass index (BMI) ≥30 compared with non-obese individuals. Prior evidence suggests protective effects from increased muscle mass and total body fat. However, the coexistence of obesity and malnutrition, and their combined impact on clinical outcomes, among hospitalized patients with ESKD receiving maintenance dialysis has remained unclear.

To address this gap, Thongprayoon and colleagues conducted a national database study using US regional and national estimates of inpatient utilization, access, charges, quality, and outcomes from the National Inpatient Sample (NIS). Investigators identified malnutrition and obesity using ICD-10 codes. Study outcomes included hospital mortality, adverse clinical events, inpatient treatments, and resource utilization, including costs and length of stay.

“To our knowledge, this is the first and largest nationally representative study to examine comprehensive in-hospital outcomes, treatments, and healthcare resource utilization among dialysis patients,” wrote investigators.

The analysis included 674,367 hospitalized adults with ESKD receiving hemodialysis (HD) or peritoneal dialysis (PD) as their maintenance modality. Overall, 125,978 patients had obesity (18.7%). Among these, 119,155 patients were not malnourished (94.6%), while 6823 had malnutrition (5.4%).

Investigators reported an overall in-hospital mortality rate of 4.6%, with higher mortality among patients with malnourished obesity (9.8%) and lower mortality among patients with non-malnourished obesity (3.6%) compared with non-obese patients (4.7%; all 

 <.001). In adjusted analyses, investigators found malnourished obesity was independently associated with an increased risk of in-hospital death (OR, 2.08). Conversely, investigators reported non-malnourished obesity was associated with a reduced risk of in-hospital mortality (OR, 0.87).

For adverse clinical outcomes, investigators linked malnourished obesity to increased risks of sepsis (OR, 2.63) and catheter-related bloodstream infection (OR, 1.70), but a decreased risk of volume overload (OR, 0.91). In contrast, investigators observed non-malnourished obesity was associated with elevated risks for all assessed adverse outcomes, including sepsis (OR, 1.07), catheter-related bloodstream infection (OR, 1.09), and volume overload (OR, 1.08).

Regarding inpatient treatments, investigators found malnourished obesity was associated with increased risks of vasopressor use (OR, 2.56), total parenteral nutrition (OR, 4.36), mechanical ventilation (OR, 1.95), and blood transfusion (OR, 1.60). Investigators also reported non-malnourished obesity was associated with lower risks of total parenteral nutrition (OR, 0.57) and blood transfusion (OR, 0.89), but higher risks of vasopressor use (OR, 1.06) and mechanical ventilation (OR, 1.85) compared with non-obese patients.

Investigators further observed patients with malnourished obesity experienced significantly longer hospital stays by 7.14 days and higher hospitalization costs by $99514 compared with patients without obesity. Similarly, investigators found patients with non-malnourished obesity had a longer length of stay by 0.14 days and higher hospitalization costs by $2811 compared with non-obese patients.

In multivariable analyses, investigators reported no significant interaction between malnutrition or obesity status and dialysis modality for in-hospital outcomes, including mortality, sepsis, catheter-related bloodstream infection, or the use of vasopressors, total parenteral nutrition, or blood transfusions (all 

However, investigators observed malnourished obesity was associated with a reduced risk of volume overload among patients receiving hemodialysis (OR, 0.89), but not among those receiving peritoneal dialysis (OR, 1.37). Investigators also found patients receiving hemodialysis had an increased need for mechanical ventilation, longer hospital stays, and higher hospitalization costs than those receiving peritoneal dialysis (all 

Wathanavasin W, Kaewput W, Thongprayoon C, Tangpanithandee S, Suppadungsuk S, Cheungpasitporn W. Association of Obesity and Malnutrition with In-Hospital Mortality and Clinical Outcomes in Patients Receiving Maintenance Dialysis: A National Database Study. 

‌Filipska A, Bohdan B, Wieczorek PP, Hudz N. Chronic kidney disease and dialysis therapy: incidence and prevalence in the world. 

https://doi.org/10.3897/pharmacia.68.e65501

Malnutrition in obese patients with end-stage kidney disease (ESKD) undergoing dialysis may negate the "obesity paradox," which suggests a survival advantage for obese patients with chronic diseases. Research indicates that malnourished obesity in ESKD patients leads to increased mortality, adverse clinical outcomes, longer hospital stays, and higher costs compared to non-malnourished patients. The study, using a national database, found that malnourished obesity is linked to higher risks of sepsis, catheter-related infections, and increased resource utilization, highlighting the importance of addressing malnutrition in this population.

A new national database study suggests malnutrition reverses the obesity survival benefit in hospitalized ESKD patients undergoing dialysis


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Malnutrition Reverses Obesity Survival Advantage in Hospitalized Patients With End Stage Kidney Disease

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

 has approved Proliv™Rx, the first at-home, physician-directed brain neuromodulation therapy for adults with 

who did not respond to ≥ 1 antidepressant.

Announced by Neurolief Inc. on January 12, 2026, the therapy can be delivered at home under physician supervision, eliminating the access and operational challenges of clinic-based treatments.

“Until now, patients struggling with difficult-to-treat depression did not have a non-pharmacological therapy option that could be administered at home", said Linda Carpenter, MD, co-lead investigator of the MOOD clinical trial and professor of psychiatry at Brown University and director of the Neuromodulation Program at Butler Hospital, in a statement. "Even though there is a tremendous need for new treatment approaches when antidepressant medications aren't working, access to interventional psychiatry services like Transcranial Magnetic Stimulation (TMS) remains limited. Now we can offer our patients Proliv™Rx therapy with continued medical supervision and the convenience of home use.”

Proliv™Rx offers focal, multi-channel, external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS), applying gentle non-invasive electrical pulses to targeted neural pathways associated with depression. A patient wears a headset with 3 pairs of integrated output electrodes that touch the scalp. The treatment has a low risk of systemic adverse events.

“Not only does Proliv™Rx introduce a novel mechanism for noninvasive neuromodulation through its actions on the occipital and trigeminal neural pathways, but it also establishes a new treatment paradigm by making evidence-based neuromodulation widely accessible, beyond the walls of the specialty clinic,” Carpenter added.

Carpenter and colleagues studied Proliv™Rx as an adjunctive therapy to antidepressants in the randomized, controlled, multicenter MOOD clinical trial, conducted from September 2021 to June 2024 at 13 clinical centers in the US and Israel.

 The study enrolled adults aged 22 to 70 years with a primary diagnosis of unipolar MDD, confirmed by a Structured Clinical Interview for DSM, with a current depressive episode duration of up to 3 years.

Participants were randomized 1:1 to the active or sham arm for 8 weeks, followed by an 8-week open-label phase. Compared to sham, patients receiving Proliv™Rx had significantly greater remission rates (21.3 % vs 6.0 %, 

 =.027) and more shifts to lower HDRS17 depression severity categories. During the open-label phase, patients receiving Proliv™Rx had a mean reduction of nearly 10 points (9.78) from baseline on the HDRS17 (

 <.0001) and achieved a remission rate of 32%.

Treatment was well-tolerated with mostly mild and transient adverse events. There were no unexpected serious adverse events.

The most common adverse event was headache, reported in 5 participants; other events included burning sensation, migraine, and pain & discomfort.

"The Proliv™Rx pivotal study results represent an important new option for patients who have not responded adequately to medications," said Mark S. George, MD, co-lead investigator of the MOOD trial and professor of psychiatry and neurology at the Medical University of South Carolina (MUSC).

 "This effective and highly accessible therapy with a favorable safety profile addresses a significant unmet need in this underserved patient population and expands how we can deliver care."

Neurolief anticipates Proliv™Rx to be available in the US in early 2026 via authorized prescribers, with initial distribution focused on health systems, behavioral health programs, and integrated care settings.

“Proliv™Rx was developed to extend brain neuromodulation beyond the limitations of traditional clinic-based care," said Scott Drees, CEO of Neurolief.

 "Patients who don't respond adequately to antidepressants face practical barriers to accessing clinic-based therapy. We are excited to make this therapy available to physicians and their patients."

Neurolief receives FDA PMA Approval for First At-Home Brain Neuromodulation Therapy for Adults Whose Depression Was Not Adequately Improved by Antidepressants. PR Newswire. Published on January 12, 2026. Accessed on January 13, 2026. 

https://www.prnewswire.com/news-releases/neurolief-receives-fda-pma-approval-for-first-at-home-brain-neuromodulation-therapy-for-adults-whose-depression-was-not-adequately-improved-by-antidepressants-302658098.html

Carpenter LL, George MS, Navarro N, Deutsch L, Leuchter AF. A novel home-based, combined occipital and trigeminal afferent stimulation therapy for major depressive disorder: Efficacy and safety results from a double-blind multicenter randomized sham-controlled study. 

The FDA has approved Proliv™Rx, an at-home brain neuromodulation therapy for adults with major depressive disorder unresponsive to antidepressants. Developed by Neurolief Inc., this therapy offers a non-pharmacological option that can be administered at home under physician supervision, addressing access issues associated with clinic-based treatments. Proliv™Rx uses external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) to target neural pathways linked to depression, with a low risk of adverse events. The therapy is expected to be available in early 2026 through authorized prescribers.

Neurolief’s physician-directed therapy brings supervised, noninvasive brain stimulation into the home for adults with MDD who have not responded to ≥ 1 antidepressant.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

FDA Approves Proliv™Rx, First At-Home Neuromodulation Device for MDD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

 scores across various anatomical sites through 72 weeks, new data suggest, indicating its consistent efficacy regardless of anatomical region.

The authors of this research, including Teppei Hagino, of Nippon Medical School Chiba Hokusoh Hospital, highlighted the head and neck region as a notably treatment-resistant region in atopic dermatitis. A prior analysis demonstrated consistent lesion improvement with tralokinumab use for moderate-to-severe disease on all bodily areas through 48 weeks.

However, Hagino and colleagues noted, the site-specific efficacy of this drug past 48 weeks has not been well described in real-world settings.

“The aim of this study is to evaluate the 72-week effectiveness of tralokinumab on four anatomical sites (head/neck, trunk, upper limbs, and lower limbs) in patients with [atopic dermatitis] in real-world clinical practice,” Hagino et al wrote.

The investigative team looked into site-specific EASI trajectories, mean percent reductions from the point of baseline, and attainment of rates of EASI 75 and EASI 100.

From October 2023 - October 2025, Hagino and coauthors carried out their prospective, real-world observational study at the Nippon Medical School Chiba Hokusoh Hospital and Gunma University. In this analysis, the investigative team did not include a control arm and involved no interventional comparisons, reflecting routine clinical practice.

Participants were patients in Japan with moderate-to-severe atopic dermatitis who received a clinical diagnosis from dermatologists in accordance with the Japanese Guidelines for Atopic Dermatitis, depending on when the atopic dermatitis diagnosis was provided. After several detailed consultations with their clinicians regarding available systemic drugs, those evaluated elected to initiate tralokinumab therapy.

The drug was administered via subcutaneous injection. This began with a loading dose of 600 mg, followed by maintenance dosing of 300 mg every 2 weeks. Healthcare professionals trained those who chose to self-administer injections in their homes prior to doing so. Throughout the study, extending to Week 72, tralokinumab use took place in combination with topical corticosteroids (TCS) ranging from class I to class III, applied twice-per-day.

Decisions regarding the specific potency, adherence to topical drugs, and duration of therapy were individualized. They were also left to the discretion of both the treating clinicians and the study participants, reflecting real-world medication variability. Hagino and coauthors evaluated tralokinumab across different bodily regions, 208 individuals who completed 72 weeks of treatment were evaluated in total. Disease severity was assessed via the EASI, with separate analyses being done for the neck and head, trunk, lower limbs, and upper limbs.

Overall, the investigative team found, across the full 72-week treatment period, tralokinumab led to sustained EASI score reductions on all anatomical sites. EASI 75 and EASI 100 achievement rates rose progressively from the 4-week through 72-week marks for each bodily area examined. Improvements were found to be most pronounced in the lower limbs, where response rates were consistently higher versus other body areas.

In contrast, Hagino et al found, percentage reductions in EASI scores over time were modestly lower for the head and neck than for the trunk or extremities.

By the 72-week mark, the proportion of individuals who attained EASI 75 was 80.0% for the trunk, 80.4% for the neck and head, 80.3% for the upper limbs, and 86.7% for the lower limbs. An EASI 100, also described as complete clearance, was seen among 37.3% of study subjects in the head and neck area, 27.4% on patients’ upper limbs, 25.0% on the trunk, and 40.0% on patients’ lower limbs.

“Treatment with tralokinumab reduced EASI scores across different anatomical sites through 72 weeks,” they wrote.

 “The results suggest that tralokinumab may be consistently effective for AD rash regardless of anatomical site.”

Shiba M, Hagino T, Uchiyama A, Saeki H, Fujimoto E, Motegi SI, Kanda N. Long-Term, Site-Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72-Week Real-World Study. J Dermatol. 2026 Jan 5. 

Hagino T, Uchiyama A, Kanda N, et al. A 48-week real-world outcome of tralokinumab treatment for atopic dermatitis: Systemic therapy-naïve versus systemic therapy-experienced patients. J Am Acad Dermatol. 2026 Jan;94(1):321-322. doi: 10.1016/j.jaad.2025.09.034. Epub 2025 Sep 15. PMID: 40962190.

Tralokinumab therapy demonstrates consistent efficacy in reducing Eczema Area and Severity Index (EASI) scores across various anatomical sites over a 72-week period. This real-world study, conducted in Japan, involved patients with moderate-to-severe atopic dermatitis. The treatment showed sustained EASI score reductions, with the most significant improvements observed in the lower limbs. While the head and neck region showed modestly lower percentage reductions, the overall results suggest tralokinumab's effectiveness in managing atopic dermatitis rash, regardless of anatomical site.

Investigators assessed the 72-week effectiveness of tralokinumab on 4 anatomical regions among patients with atopic dermatitis in real-world clinical practice.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Tralokinumab Consistently Effective for Eczema Regardless of Anatomical Site

Sonalika Khachikian, MD, is an endocrinologist at Monument Health.

Videos

Management of thyroid eye disease (TED) may require adjunctive medical therapies and surgical intervention, particularly in patients with severe, refractory, or high-risk disease features. 


Video Series

Adjunctive Therapies, Surgery, and Special Populations in TED

The report details the disease burden, mortality, and quality of care trends for 5 major risk factors and the 5 leading causes of CVD death.

JACC Inaugural Cardiovascular Studies Report Highlights Progress and Potential for Growth

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Type 1 Diabetes

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Dementia and Alzheimer Disease

Alzheimer Disease condition center page, resources on the topics of medical news and expert insight into Alzheimer's can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dementa and Alzheimer disease research, treatment, and drug development.

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

HCPLive 5 Stories in Under 5: Week of 01/04

This systematic search of databases was conducted to identify research evaluating drugs used for prurigo nodularis (PN).

Dupilumab Most Effective Among Standard Drugs, Biologics in Prurigo Nodularis

In a multicenter analysis, ZEBRA, an AI-assisted pathology tool, showed high sensitivity and specificity for detecting Fabry nephropathy in renal biopsies.


RDR Alert®

The Rare Disease Report page is a resource for medical news and expert insights on rare diseases. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for sickle cell disease, multiple myeloma, and more.

AI-Based ZEBRA Model May Improve Detection of Fabry Nephropathy on Kidney Biopsy

Patients with idiopathic pulmonary fibrosis treated with the STAT3 inhibitor TTI-101 had greater reductions in lung fibrosis scores and IL-6 levels than placebo at 12 weeks.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonary Fibrosis

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

David Armstrong, MD, PhD, is a distinguished professor of surgery and neurological surgery at Keck School of Medicine of USC.

Armstrong discusses the positive time-to-healing data from the phase 2 LEGenD-1 study, investigating anatomically targeted delivery of AMG0001.

Gene Therapy Accelerates Ulcer Healing in Limb-Threatening Ischemia, With David Armstrong, DPM, PhD

A groundbreaking study reveals that combining ixekizumab and tirzepatide significantly improves outcomes for adults with psoriatic arthritis and obesity.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Psoriatic Arthritis

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.

Tirzepatide Boosts Izekizumab Efficacy for PsA and Obesity Disease Control

Bristol Myers Squibb has reported positive results from the ongoing SCOUT-HCM trial, demonstrating mavacamten’s efficacy in reducing Valsalva LVOT.

Cardiomyopathy

SCOUT-HCM: Mavacamten Achieves Positive Results in Adolescents with Obstructive HCM

A retrospective analysis links low pretransplant exercise tolerance with reduced skeletal muscle recovery and persistent sarcopenia risk after living donor kidney transplantation in CKD.

Latest News

FDA Clears AI Program Powering Kardia 12L Electrogram for 5 New Cardiac Determinations

ADA’s Obesity Association Releases Guidelines for Use of Obesity Medications

Malnutrition Reverses Obesity Survival Advantage in Hospitalized Patients With End Stage Kidney Disease

FDA Approves Proliv™Rx, First At-Home Neuromodulation Device for MDD

Tralokinumab Consistently Effective for Eczema Regardless of Anatomical Site